FMR LLC decreased its holdings in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 0.3% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 4,907,846 shares of the biotechnology company's stock after selling 14,709 shares during the quarter. FMR LLC owned approximately 8.09% of Ascendis Pharma A/S worth $732,790,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds have also recently bought and sold shares of ASND. Signaturefd LLC raised its position in shares of Ascendis Pharma A/S by 13.2% in the 3rd quarter. Signaturefd LLC now owns 686 shares of the biotechnology company's stock valued at $102,000 after purchasing an additional 80 shares in the last quarter. Profund Advisors LLC increased its stake in shares of Ascendis Pharma A/S by 3.0% in the second quarter. Profund Advisors LLC now owns 2,919 shares of the biotechnology company's stock worth $398,000 after buying an additional 85 shares during the last quarter. Rhumbline Advisers raised its holdings in Ascendis Pharma A/S by 10.3% in the second quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company's stock valued at $209,000 after acquiring an additional 143 shares in the last quarter. Thrivent Financial for Lutherans boosted its stake in Ascendis Pharma A/S by 0.3% during the 3rd quarter. Thrivent Financial for Lutherans now owns 78,473 shares of the biotechnology company's stock valued at $11,717,000 after acquiring an additional 228 shares during the last quarter. Finally, Avior Wealth Management LLC grew its holdings in Ascendis Pharma A/S by 3.0% during the 3rd quarter. Avior Wealth Management LLC now owns 8,212 shares of the biotechnology company's stock worth $1,226,000 after acquiring an additional 240 shares in the last quarter.
Ascendis Pharma A/S Stock Performance
Shares of NASDAQ:ASND traded down $0.24 during midday trading on Friday, reaching $136.08. The company had a trading volume of 491,959 shares, compared to its average volume of 451,948. The company has a fifty day simple moving average of $132.21 and a two-hundred day simple moving average of $132.24. The firm has a market cap of $8.25 billion, a price-to-earnings ratio of -16.87 and a beta of 0.66. Ascendis Pharma A/S has a 1-year low of $97.86 and a 1-year high of $161.00.
Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last released its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The firm had revenue of $38.75 million for the quarter, compared to analyst estimates of $94.74 million. Analysts expect that Ascendis Pharma A/S will post -7.45 EPS for the current year.
Analysts Set New Price Targets
A number of research analysts have commented on the company. Evercore ISI increased their target price on Ascendis Pharma A/S from $191.00 to $205.00 and gave the stock an "outperform" rating in a report on Tuesday, September 17th. Jefferies Financial Group raised their price target on Ascendis Pharma A/S from $174.00 to $196.00 and gave the stock a "buy" rating in a report on Tuesday, August 13th. The Goldman Sachs Group upped their price objective on Ascendis Pharma A/S from $180.00 to $200.00 and gave the stock a "buy" rating in a research note on Tuesday, September 17th. Wells Fargo & Company boosted their price target on shares of Ascendis Pharma A/S from $264.00 to $289.00 and gave the company an "overweight" rating in a report on Tuesday, September 17th. Finally, Oppenheimer cut their target price on Ascendis Pharma A/S from $190.00 to $180.00 and set an "outperform" rating for the company in a research report on Friday, November 15th. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $191.77.
Check Out Our Latest Research Report on ASND
Ascendis Pharma A/S Company Profile
(
Free Report)
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
Further Reading
Before you consider Ascendis Pharma A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascendis Pharma A/S wasn't on the list.
While Ascendis Pharma A/S currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
